Viracta: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Clinical Trial Grant
Awarded By
Viracta Therapeutics, Inc.
Start Date
September 22, 2023
End Date
January 16, 2026
Awarded By
Viracta Therapeutics, Inc.
Start Date
September 22, 2023
End Date
January 16, 2026